Atorvastatin free acid is shown below as structural formula I: In addition to the crystalline polymorphs of atorvastatin calcium discussed supra, various salts of atorvastatin have been described, for example, in US Patent No. Table 3. More preferred coatings include those containing hydroxypropyl cellulose and hydroxypropyl methylcellulose; or polyvinyl alcohol and polyethylene glycol. The oral dosage unit compositions of the present invention can have any form suitable for oral administration.
Atorvastatin free acid is shown below as structural formula I: In addition to the crystalline polymorphs of atorvastatin calcium discussed supra, various salts of atorvastatin have been described, for example, in US Patent No.
The compositions are useful for preparation of monolithic tablets containing the atorvastatin as the only active agent present or combined with one or more additional active agents other than atorvastatin. However, atorvastatin is susceptible to heat, moisture, low pH environment, and light. The lubricated blend was transferred to a suitable roller compactor TFC Labo, 15mm roll and compacted at a suitable pressure bar , suitable roll speed rpm , maintaining a suitable roll gap 1.
The review provides a comprehensive overview of the research on various strategies, offers both theoretical and practical guidelines for strategy transformation that companies can use to prolong the market exclusivity, and identifies knowledge gaps that needed to be addressed in order to improve efficiency in policy design. Food was returned 4 hours after dosing, and blood was drawn at pre-dose, 0. More particularly, the molar ratio of the alkalizing additive to atorvastatin is present from 1 : 1 to 4: 1 , 1 : 1 to 3 : 1 , 1 : 1 to 2: 1 or it is 1 : 1. Where the atorvastatin and sodium bicarbonate or L-arginine are present in combination with one or more additional pharmaceutically active agents, the release rate of any pharmaceutical agent present may be controlled, independent of the release of other agents. The percentage of alorvastatin, and optional additional active agent s in the compositions of the present invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained, A dose employed may be determined by a physician or qualified medical professional, and depends upon the desired therapeutic effect, the duration of the treatment, and the condition of the patient.
One 1. Table 8. Table 7. The compositions are prepared as bulk drug compositions and also as oral dosage units, such as tablets or capsules, and particularly tablets. When packaged in the form of tablets, powders, granules, or within capsules, atorvastatin may be further destabilized by contact with the molecular moieties of other components.
The amount of additional active agent or agents which may be present will depend on the therapeutically desirable amount of additional active agent or agents and therapeutically desirable amount of atorvastatin per dosage unit, maximum feasible dosage unit size, and the physical and chemical properties of the optional additional active agent or agents. The pharmacokinetic data obtained from this study is listed in Table 8. This systematic review explores various strategic and tactical management approaches by synthesizing the relevant literature and practical examples on patent expiration strategies.